SOURCE: Active Biotech

August 06, 2009 13:20 ET

Active Biotech AB Interim report January-June 2009

LUND, SWEDEN--(Marketwire - August 6, 2009) - * Laquinimod -- BRAVO Phase III trial fully enrolled

* 57-57 -- explorative clinical trial initiated
* RhuDex™ -- preclinical tests in progress
* ANYARA -- Phase III trial fully enrolled
* TASQ -- Phase II trial fully enrolled
* ISI - target molecule for Q compounds published
* Net sales of SEK 5.2 M (5.8)
* Operating loss of SEK 118.5 M (loss: 104.7)
* Loss after tax of SEK 118.6 M (loss: 99.3)
* Loss per share for the period of SEK 2.22 (loss 2.07)
* Implemented rights issue contributed approximately SEK 249 M
* Number of shares at the end of the period (incl. warrants),
  65,052,238
 
This report is also available at www.activebiotech.com



This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.



Copyright © Hugin AS 2009. All rights reserved.

Contact Information

  • For further information, please contact:
    Tomas Leanderson
    President and CEO
    Tel: +46 (0)46-19 20 95

    Göran Forsberg
    VP Investor Relations & Business Development

    Tel: +46 (0)46-19 11 54

    Hans Kolam
    CFO

    Tel: +46 (0)46-19 20 44

    Active Biotech AB
    (Corp. Reg. No. 556223-9227)
    PO Box 724, SE-220 07 Lund
    Sweden
    Tel: +46 (0)46-19 20 00
    Fax: +46 (0)46-19 11 00